INTRODUCTION

Heart failure, especially with reduced ejection fraction, is a complex syndrome characterized by ongoing progression of the disease without any external triggering factors. Cardiac structure and function continue to deteriorate. This progression is believed to be powered by multiple vicious circles that eventually result in end-stage pump failure and patient’s death. They include cardiomyocyte apoptosis and necrosis, resulting in net loss of cardiomyocytes, mitochondrial dysfunction, impaired cardiomyocytes Ca²⁺ handling, fibrosis, neurohormonal activation and ischaemia. Currently, heart failure therapy is aimed at inhibiting detrimental neurohormonal activation.
(ACE inhibitors, sartans, beta blockers) and is able to merely slow down the progression of the disease rather than stop it or preferably reverse it.

Heart failure is emerging as an energy starvation state, that is cardiomyocytes are ATP depleted. Studies suggest that intracellular ATP concentration may be 25%-30% lower in the failing human heart and this process can contribute to heart failure progression. This is probably a multifactorial phenomenon, resulting from reduced oxygen delivery, impaired oxygen utilization in the face of increased oxygen demand (due to increased afterload). So far therapeutic attempts to address it have largely been unsuccessful. They were mainly focused on increasing the concentration of haemoglobin, an oxygen-carrying protein. But neither erythropoietin analogs that increased haemoglobin concentration nor intravenous iron that provided an essential element not only for haemoglobin, but also other enzymes involved in cardiac energetics provided unequivocal benefits in human clinical trials, though recent data, including our own work, suggest that iron may be of some value here.

Another drastically different approach involves facilitation of oxygen dissociation from haemoglobin in the tissues. Only 25% of oxygen transported by haemoglobin (Hb) dissociates and is retained in tissues, while the remaining three quarters return with venous blood. Under low tissue oxygen content, the extraction rate increases. Endogenous allosteric regulators (2,3-bisphospho-d-glycerate (BPG)) bind to the allosteric cavity of Hb, stabilizing the deoxygenated form of Hb, and oxygen affinity is reduced favouring further oxygen dissociation and retention by tissues. Oxygen extraction rate increases even further, but never exceeds 75%. So one-quarter of oxygen is returned with venous blood being a potential target for intervention. In this regard, myo-inositol trispyrophosphate (ITPP), a membrane-permeant allosteric effector of haemoglobin, has been shown to enhance the oxygen release capacity of red blood cells by lowering the affinity of haemoglobin for oxygen, thus enabling to counteract the effects of hypoxia. Indeed, we have previously shown that ITPP shifts the oxygen dissociation curve downward, therefore increases tissue oxygen delivery, especially to hypoxic tumours. This is accompanied by a potent anti-cancer effect in various tumour models in the mouse. Thus, ITPP anti-cancer effects in animal models involve better oxygen delivery to the tumour as part of the vessel normalization process which is the key to the effectiveness of the treatment.

Hypoxia-inducible factor (HIF) is emerging as the main mediator of hypoxia and ischaemia. Highly conserved, it plays a pivotal role in the transcriptional response to changes in oxygen availability. HIF-1 comprises two subunits, the α-subunit, which is regulated in an oxygen-dependent manner and β-subunit that is constitutively expressed. Molecular oxygen allows for HIF-1α hydroxylation by prolyl hydroxylase 2 (PHD2) and its rapid proteosomal degradation after von Hippel-Lindau protein binding and ubiquitinylation. On the other hand, hypoxia impairs hydroxylation, which results in HIF-1α stabilization, heterodimerization with HIF-1β. The heterodimer (HIF-1) enters the nucleus and binds to the hypoxia response element (HRE) to start the transcription of the subsequent hypoxia-inducible genes. Thus, HIF-1 controls the expression of multiple genes that regulate cell survival, cell metabolism and angiogenesis in hypoxic conditions. In a short term, HIF-1 activation can be beneficial by switching the cardiac metabolism to anaerobic pathway, reducing energy consumption by down-regulating Ca²⁺ handling proteins (SERCA2a) that utilize enormous quantities of ATP and stimulating angiogenesis. However, long-term HIF-1 activation can be detrimental, by inducing energy starvation through reduced fatty acid oxidation and impaired mitochondrial biogenesis and impairing Ca²⁺ handling. Furthermore, we have recently shown that angiogenesis stimulated by HIF-1 in tumour results in the formation of defective vessels that are leaky and do not provide adequate blood supply. In this context, we have demonstrated that ITPP reduces HIF-1α expression by vascular endothelial cells, providing anti-tumour effects. Although the extent and dynamics of HIF-1 expression in hypoxic tumour cells as well as its response to ITPP have been studied in details, behaviour of this system in cardiomyocytes in the context of ischaemic cardiac diseases is largely unknown as well as the effect of ITPP in their treatment.

Thus, the first aim of our study was to test the hypothesis that ITPP has beneficial effect on post-MI left ventricular remodelling and heart failure in the rat model. The second aim was to verify the hypothesis that HIF-1 expression is rapidly stimulated by hypoxia and that this HIF-1 overexpression is prevented by ITPP in a model of murine blood-perfused cardiomyocytes.

2 MATERIALS AND METHODS

Male Wistar rats (n = 35) 280-320 g and female C57Bl6 mice were used in this project. All animal procedures conformed to the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes. The study was approved by the local ethics committee (Second Warsaw Local Ethics Committee for Animal Experimentation).

2.1 Heart failure in vivo rat study—experimental design

Rats were subjected to induction of myocardial infarction (MI group) or sham operation (Sh group). After 4 weeks of follow-up, the animals underwent echocardiographic imaging. Only rats with large MI (≥40% of the LV) were enrolled to MI group in this study (5 rats were excluded). Both MI and Sh rats were randomized into two subgroups: ITPP group received 2 intraperitoneal doses of ITPP (1.5 g/kg) per week (on Monday and Tuesday), a total of eight doses over 4 weeks (see Figure 1 for study protocol), while saline group received corresponding saline injections. We have previously shown in a mouse model that such dosing regimen provides long-term improvement of oxygen delivery to the tumour and survival benefits. Echocardiography was performed weekly. Eight weeks after MI induction/sham operation, the rats underwent final echocardiographic imaging.
imaging and ketamine HCl/xylazine overdose was given to euthanize the animals and subsequently hearts were excised for biochemical and cellular studies.

2.1.1 | Induction of myocardial infarction

Rats were anaesthetized with ketamine HCl and xylazine (100 mg/kg and 5 mg/kg b.wt., respectively, ip), left thoracotomy was performed, the heart was externalized, and a suture (5-0 silk) was placed around proximal left coronary artery. In Sh animals, it was left loose, and in MI animals, it was tied. Buprenorphine (1 mg/kg b.wt., ip) was given as a post-operative analgesia. Within 4 weeks, post-MI mortality was 40%. The vast majority of these deaths (18 animals) occurred during first 2 days after induction of MI. No death occurred after randomization to ITPP/saline groups 4 weeks after MI induction and completion of the study.

2.1.2 | Echocardiography imaging

Echocardiography was performed using SonoScape S2 (Sonoscape Medical) with high-frequency linear 8 to 15 MHz probe. Each rat was examined 4, 5, 6, 7 and 8 weeks after the surgery. Under light isoflurane anaesthesia, LV end-diastolic and end-systolic diameters were determined from the long-axis view at the aortic valve level. Regional LV wall motion abnormalities were assessed using the wall motion index (WMI). Contractility of 12 wall segments visualized in the midpapillary short-axis view and 11 segments visualized in the long-axis view was graded as 1 (normal) or 0 (abnormal), and the total WMI was calculated (Figure 1C). The normal hearts had WMI = 23. Our previous results revealed that WMI closely correlated with infarct size and that WMI = 15 corresponded to infarct size ~40%. LV ejection fraction (LVEF) was calculated as (LV diastolic area—LV systolic area)/LV diastolic area. All measurements were obtained by one observer blinded to the study groups.

2.1.3 | Myocyte isolation

After excision of the heart, the aorta was cannulated and retrogradely perfused for 5 minutes with nominally Ca\(^{2+}\)-free solution containing 100 μmol/L of EGTA of the following composition (in mmol/L): 144 NaCl, 5 KCl, 1 MgCl\(_2\), 0.43 NaH\(_2\)PO\(_4\), 10 N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES), 11 glucose and 5 sodium pyruvate. The pH of the solution was adjusted with NaOH to 7.3 Initial washout period was followed by 20 minutes of perfusion with Ca\(^{2+}\) free Tyrode solution containing 20 mg collagenase B (Roche) and 3 mg protease (Sigma) per 30 mL. Thereafter, the right ventricle was separated and discarded. LV was placed in the glass dish and mechanically disrupted. The cell suspension was filtered and allowed to sediment. The supernatant was discarded, and cells were washed twice with Tyrode's solution, the Ca\(^{2+}\) concentration being increased gradually to 1 mmol/L. The myocytes were superfused at 37°C with Tyrode's solution containing 1.8 mmol/l Ca\(^{2+}\).
were immortalized according to our previously described method patented for cell keeping a stable phenotype (CNRS patent number 99-169, world patent N13/521715). Three clones were obtained from rat cardiomyocytic cell primary cultures RCmCl.4, RCmCl.13 and RCmCl.18, and three clones were selected MCmCl.4, MCmCl.10 and MCmCl.14. After characterization and sorting of the cells that are properly expressing cardiomyocytic markers: myosin, desmin and α-actinin (anti-mysin heavy chain Fluorescein-conjugated Antibody, anti-Hu/Mo desmin Goat IgG1 and antimouse α actinin IgG2-FITC labelled, were from R and D) and displayed contractility, the cells were cloned by flow cytometry cell sorting. Mouse derived clone 4 was selected and multiplied (MCmCl4).

2.2.2 | HIF-1α production by cardiomyocytes submitted to hypoxia compared to normoxia

ELISA quantification HIF-1α production by cardiomyocytes
Cells were subjected to hypoxia pO₂ = 7.6 Torr = 1%, for various time lapses (from 1 to 12 hours) then lysed, and total HIF-1α was measured by ELISA (mouse total HIF-1α kit, R&D systems).

HIF-1α induction, distribution and dynamics of redistribution in cardiomyocytes upon hypoxia treatment
Murine cardiomyocytes were hypoxia-treated (1% O₂) for 1-12 hours, and HIF-1α induction was detected by anti-HIF-1α antibodies (R and D), evidenced by FITC-labelled secondary antibodies and assessed by fluorescence microscopy (Zeiss axiovert 200M); nuclei were labelled by DAPI (UV and blue light detection). Image analysis for the cellular distribution was done using the Axiovision program.

2.2.3 | In vitro design of RBC-ITPP effect of oxygen release on cardiomyocytes

Cardiomyocytes were cultured on microscope slides quadriderm (Dutcher dish) previously coated with 300 µL of 0.2% gelatine aqueous solution, in sterile conditions then dried. Cardiomyocytes (5.10^5 cells in 3 mL of complete DMEM (10% SVF + 1% Penicillin-streptomycin + 0.1% Fungizone) were seeded and grown for two days at 37°C in 5% CO₂ atmosphere. For flow experiments, cultures were submitted to hypoxia (O₂, 1%) for 3 hours then further treated for 2 hours, by medium maintained either in hypoxia or in normoxia, either containing TPP-charged (mRBCs+) or non-treated (mRBCs−) murine red blood cells. 50 µM ITPP and IHP (inositol hexaphosphate) solutions were used as controls. The role of the shear stress and flow were assessed by flowing the medium containing or not mouse erythrocytes (10^7 cells/mL) that have been previously charged by ITPP (mRBC+) comparatively to native erythrocytes (mRBC−).

Controls were obtained by the same treatments in normoxia as well as treatment with normal culture medium in flow conditions.

When indicated, cells were first incubated for 3 hours in hypoxia and then submitted to flow and maintained for 2 hours.

2.2.4 | ITPP-mRBC loading

Mouse erythrocytes were loaded by addition of a 78 mmol/L ITPP solution in saline to mRBC suspension (1.2 x 10^10 cells/mL) and 1 hour incubation at 37°C. Washed cells were further used at 10^7 cells/mL in the appropriate medium for the flow experiments.

2.2.5 | ITPP-mRBC mediated suppression of hypoxia-induced molecules in cardiomyocytes in vitro

Murine clone 4 cells, selected and allowed to multiply (MCmCl4), were subjected to hypoxia PO₂ = 7.6 Torr = 1%; for various time lapses (from 1 to 12 hours) and tested for HIF-1α expression.

2.3 | Statistical analysis

All data are expressed as means ± SEM. Normal data distribution was verified by Shapiro-Wilk test while homogeneity of variances by Bartlett’s test. Differences among groups were tested by one-way analysis of variance with a Tukey test as post hoc test or Kruskal-Wallis test with a post hoc Dunnett-Tukey-Kramer test (R version 3.2.0). P < .05 was accepted as a level of significance.

In vitro cell data, are expressed as means ± SEM. All statistical analyses were performed using GraphPad Prism 7.0 software.

P values were determined by Student’s t test. A P value of less than 0.05 was considered statistically significant. *Indicates statistically significant differences (P < .05).

3 | RESULTS

3.1 | Heart failure in vivo rat study

3.1.1 | Infarct size, morphological parameters and mortality

Rats were subjected to induction of MI or sham (Sh) operation, followed for 4 weeks so that MI rats could develop stable heart failure and then treated for another 4 weeks with either ITPP or saline (Figure 1). The mean infarct size evaluated by transthoracic echocardiography did not differ between MI and MI + ITPP groups at randomization or at the end of the study (4 and 8 weeks after MI induction, respectively) (Table 1). There were no differences in body weight between MI and Sh animals at any time point after the surgery. No death occurred in either study group after beginning of ITPP/saline injections.
3.1.2 | Haemodynamic function and left ventricular dimensions

Large myocardial infarction induced LV remodelling and impaired LV systolic function, reflected by progressive increase of LV end-diastolic volume and decrease of LV ejection fraction (Figure 2). ITPP essentially halted the increase of LV dilation and significantly reduced impairment of LV ejection fraction, while it had no effect on sham-operated rats (Figure 2).

**TABLE 1** The effect of ITPP on the morphometric and haemodynamic parameters in sham operated and post-myocardial infarction rats

|                          | Sh (n = 6)    | Sh + ITPP (n = 6) | MI (n = 6)    | MI + ITPP (n = 6) |
|--------------------------|--------------|-------------------|--------------|------------------|
| Infarct size at 4 wk (%) | -            | -                 | 47.11 ± 2.43 | 48.62 ± 4.17     |
| Infarct size at 8 wk (%) | -            | -                 | 48.30 ± 3.29 | 47.22 ± 3.38     |
| Body weight (g)          | 410 ± 12     | 402 ± 17          | 411 ± 20     | 415 ± 28         |

Note: Means ± SEM.
Abbreviations: BW, body weight; MI, myocardial infarction; Sh, sham operation.

**FIGURE 2** The effect of ITPP on echocardiographic parameters in sham operated (Sh) and myocardial infarction (MI) rats. A. The representative echocardiographic images of LV end-diastolic area from the long-axis parasternal view. (a) Sh; (b) Sh + ITPP; (c) MI; (d) MI + ITPP. LV, left ventricle; LA, left atrium. Dashed line marks the endocardial surface. While in both sham images the LV cavity is oblong in shape, it is almost spherical in MI image; B. Left ventricular diastolic area (upper panel) and ejection fraction (lower panel). *P < .05 MI + ITPP vs MI.
3.1.3 | Contractile function of cardiomyocytes isolated from the rat left ventricle

Eight weeks after induction of MI and five days after the last dose of ITPP, contractile performance of freshly isolated cardiomyocytes was evaluated (Figure 3A and B). We found that contractile function of LV cardiomyocytes surviving after MI was preserved. Moreover, the amplitude of the cell shortening was even slightly increased (Figure 3C). This is probably a result of the adaptive process of the cardiomyocytes surviving MI to sustain left ventricular function after the loss of numerous cardiomyocytes. As a result of increased amplitude of cell shortening, both time to peak of contraction and time to 90% of relaxation were longer as compared to these parameters in cardiomyocytes from sham-operated rats (Figure 3D and E, respectively). The rates of cardiomyocyte contraction and relaxation were not changed (Figure 3F and G, respectively).

ITPP administration after MI did not affect cardiomyocytes function and did not affect their functional remodelling. On the other hand, in sham-operated rats ITPP slightly prolonged the time of contraction and relaxation (Figure 3D and E) and showed a trend towards slower kinetics; however, it was statistically insignificant (Figure 3F and G).

3.2 | Cardiomyocytic cell line experiments

3.2.1 | HIF-1α is induced, stably expressed and redistributes in cardiomyocytes upon hypoxia treatment

Cardiomyocytic cells from newborn mice, established as non-transformed immortalized line, were submitted to flow cytometry cloning. Clones were characterized for the expression of cardiomyocytic markers as myosin, desmin and α-actinin. Figure 4 shows the expression of α-actinin by cloned MCMCl4 cells (Figure 4A).

When submitted to hypoxia treatment (pO2 = 1%) for 3 hours, cardiomyocytes displayed induced HIF-1α expression (Figure 4B, b) as compared to control cells (Figure 4B, a) together with a redistribution of its localization from the cytosol to the nucleus and a clear
increase of the size of the cell nuclei (Figure 4B a,b insets). Upon hypoxia treatment for 12 hours as shown on Figure 4B, d compared to the control on Figure 4B, c, there was accumulation of HIF-1α in the perinuclear cytosol and the nuclei. The kinetics of HIF-1α synthesis and production by cardiomyocytes under hypoxia (Figure 4C) indicates that HIF-1α accumulated actively during the first 3 hours in hypoxia and reached a plateau by 6 hours incubation and then decreased after 12 hours (data not shown).

HIF-1α induction shown by confocal microscopy analysis in cardiomyocytes upon hypoxia treatment for 3 hours (Figure 4C) was stable for 12 hours under hypoxia. HIF-1α redistributed from the cytosol to the nucleus as shown by image analysis of the fluorescence distribution of FTC anti-HIF-1α as compared to the DAPI as nuclei specific tracer. Figure 4D displays the detection of HIF-1α basically expressed in the cytosol of cardiomyocytes in normoxia. No colocalization with the nuclei was observed when cells were in normoxia (Figure 4D a and c) but induced HIF-1α colocalized with the nuclei when cells were treated for 3 hours by hypoxia (1%) (Figure 4D b and d).

The quantification of the fluorescence distribution for DAPI compared to fluorescein (HIF-1α) at the one-cell level (Figure 4D c and d, arrows) and the whole population (Figure 4D a and b, arrows) show that upon hypoxia the average size of the nuclei was doubled (Figure 4D, b compared to Figure 4D, a) and the HIF-1α was detected both in the nucleus as well as in the perinuclear region of the cytosol (Figure 4D a, arrow).

3.2.2 | ITPP-charged murine erythocytes reduce HIF-1α expression in hypoxia-treated cardiomyocytes under flow conditions

Cardiomyocyte cultures express HIF-1α when submitted to hypoxia (O2 1%) for 3 hours. To test the ability of ITPP-charged red blood cells to deliver oxygen and alleviate hypoxia, cardiomyocytes were perfused with media containing mouse erythrocytes either native, as control, or previously charged with ITPP, as described. Cardiomyocytes were further treated for 2 hours, in various conditions by medium containing mouse erythrocytes 10^7 cells/mL that were previously charged by ITPP (RBC-ITPP⁺) compared to non-charged native erythrocytes (RBC-ITPP⁻). Figure 5A indicates that HIF-1α, induced by hypoxia was not modified by the
addition of non-modified red blood cells, while a HIF-1α production was significantly reduced by 30% after 2 hours of treatment by RBC-ITPP⁺. As the effect of the blood-borne molecules and cells delivery is linked to the dynamics and the shear stress effect, we tested the effect of ITPP-charged erythrocytes on hypoxic cardiomyocytes in flow conditions. We designed and used a sealed flow chamber which allows the controlled flow and gas conditions as shown on Figure 5B. As summarized on Figure 5C, under normoxic conditions, HIF-1α protein was expressed at a low level. This was not significantly modified by the control medium or by the same medium containing either the native mouse red blood cells or the ITPP-loaded mouse red blood cells. Under flow, hypoxia caused a marked induction of HIF-1α expression as compared to hypoxia without shear stress effect. This is confirmed by the increased effect observed when the flow was applied with medium containing red blood cells as compared to RBC-ITPP + action in static conditions (Figure 5B), thus underlining the shear stress effect. Indeed, HIF-1α induction was clearly reversed when ITPP-charged erythrocytes (RBC-ITPP⁺) were perfused onto the hypoxic cardiomyocytes. Inhibition of HIF-1α expression by cardiomyocytes in hypoxia was due to the oxygen release effect by ITPP-charged erythrocytes since non-modified erythrocytes had no influence. Moreover, this effect was not caused by ITPP itself on cardiomyocytes (Figure 5C), nor by the shear stress alone as indicated by the lack of effect of a 50 μmol/L solution of ITPP in medium, as compared to the IHP 50 μmol/L solution as control (Figure 5C).

Hypoxia was the main parameter monitoring HIF-1α production by cardiomyocytes as shown by the control series performed in normoxia. In normoxic conditions, no effect was detected on HIF-1α by the same treatments in flow conditions (Figure 5C).

In order to rule out the possible side effects of ITPP or its control metabolite, inositol hexaphosphate (IHP), on the cardiomyocytes, we checked for their effect on cardiomyocytes growth and viability.

**FIGURE 5** HIF-1α in cardiomyocytes is reduced by ITPP-charged red blood cells (RBC-ITPP⁺)-mediated oxygen delivery in flow conditions. A, Effect of RBC-ITPP⁺ on the modulation of HIF-1α expression in hypoxia, as compared to RBC-ITPP⁻. HIF-1α was detected by ELISA, experiments were performed in triplicates. Data represent the mean values ± SEM from four experiments, in triplicates. B, Flow chamber design for the in flow modulation of a cardiomyocytic cell culture. C, Modulation of cardiomyocytes production of HIF-1α under hypoxia by flow borne ITPP-charged RBC-ITPP⁺ as compared to non-modified RBC-ITPP⁻ erythrocytes. Controls are performed in the presence of medium with and without applied flow, and in the presence of ITPP (50 μmol/L) or IHP (50 μmol/L). Data represent the mean values ± SEM from three experiments in triplicates.
in a dose-response assay where the cell concentration was measured after 96 hours in culture in the presence of ITPP or IHP (from 100 mmol/L). Their potential direct influence on HIF-1α production in the same flow conditions as described above for murine erythrocytes charged by ITPP was assessed. These experiments did not reveal any effect on either the growth or the viability of the cardiomyocytes cultures as shown on Figure 6A.

As ITPP-charged erythrocytes counteract the effects of hypoxia on cardiomyocytes and do not exert any toxicity, we addressed the question of cardiomyocytes remodelling under such treatment.

The evolution of the nuclei size was followed. Figure 6B shows that the cardiomyocytic cells, when hypoxia-treated as above described, displayed an increased size evidenced by the number of pixels estimated for the biggest nuclei (Figure 6B, C). The size was reduced upon 2 hours of treatment by flow borne RBC-ITPP + similarly to 20 hours normoxia post-treatment (Figure 6B and C).

4 | DISCUSSION

Here, we show for the first time that ITPP, a novel membrane-permeant allosteric effector of haemoglobin that enhances the oxygen release capacity of RBC by lowering the affinity of Hb for oxygen, partially prevents post-MI left ventricular dilation and impairment of contractility in the rat model of post-MI heart failure, most important markers of heart failure progression and prognosis. These beneficial effects do not seem to result from improved contractile

**FIGURE 6** Effect of ITPP and RBC-ITPP on cardiomyocytic cell cultures. A, ITPP and RBC-ITPP+ effect of MCMCl4 cells upon hypoxia (1%, 3 h). Controls are treated by ITPP (50 μmol/L) and IHP (50 μmol/L). B, Increase of the cardiomyocytes nuclei size was observed upon hypoxia treatment (pO2 1%) for 3 h and effect of RBC-ITPP treatment in flow (20 μL/min) for 2 h, as compared to normoxia post-treatment for 22 h. C, Analysis of the cell evolution in hypoxia (3 and 5 h, followed by a 22 h normoxia post-treatment or a 2 h RBC-ITPP+ flow treatment). Data are mean values ± SEM from three experiments performed in triplicates
function of LV cardiomyocytes. Furthermore, ITPP administration raises no safety issues.

Moreover, our experiments in cultured murine cardiomyocytes demonstrated that when these cells were subjected to hypoxia, they exhibited overexpression of hypoxia-inducible factor-1 (HIF-1α) that additionally changed its location from cytoplasmic to nuclear. This HIF-1α overexpression could be prevented by perfusion with red blood cells charged with ITPP. Thus, we show that ITPP is a promising agent that could prevent progression of heart failure and that its effect may go beyond simple improvement of oxygen delivery to ischaemic tissues, namely involve prevention of HIF-1 overexpression and presumably its detrimental effects.

Ischaemia (lack of adequate blood flow) and hypoxia (lack of adequate tissue oxygen) are underestimated potential mechanisms of heart failure progression. Heart failure is accompanied by both myocardial hypertrophy and increased LV diastolic pressure that favours increased external compression of coronary arteries and reduction of coronary flow, especially in the subendocardial layer. Indeed, hypertrophy was shown to induce subendocardial anaerobic metabolism in dogs with aortic stenosis. Patients with dilated cardiomyopathy had reduced coronary reserve and this reduction correlated positively with fibrosis and negatively with ejection fraction. Furthermore, impaired coronary flow reserve correlated with increased serum cardiac troponin T, suggesting ongoing necrosis. Moreover, subendocardial ischaemia was associated with mitochondrial impairment and contractile dysfunction and induction of free radical production that could be prevented by anti-oxidant interventions. Thus, large body of evidence supports the notion that ischaemia, ongoing low-grade ischaemia or bouts of demand-induced ischaemia triggering myocardial stunning or hibernation, accompanies heart failure and may contribute to its progression. Moreover, in the post-MI setting, the necrotic core is surrounded by a borderzone of live but often ischaemic tissue. With adequate oxygen delivery, it can be salvaged as healthy myocardium, but inadequate tissue oxygen may facilitate its eventual necrosis and infarct extension and further adverse remodelling. Moreover, the alleviation of ischaemia, in the setting of left ventricular dysfunction and heart failure, may be crucial for the progression.

As far as we know, we were the first to utilize a novel agent, ITPP, to improve oxygen delivery, reduce ischaemia and prevent its contribution to progression of LV dilation and impairment of function. We showed in a well-established animal model of post-MI heart failure, exhibiting all signs of human heart failure (progressive LV dilation, worsening of LV function) that ITPP administered over 1 month virtually halted LV dilation and impairment of EF, two most important predictors of both HF incidence after MI and prognosis in established HF. This improvement of global LV function and dilation was not accompanied by improvement of contractile function of isolated left ventricular cardiomyocytes. These results suggest that ITPP may inhibit the loss of working cardiomyocytes rather than improve their function. Indeed, cardiomyocyte loss through apoptosis and necrosis and the most recently described mechanism of programmed cell loss called necroptosis followed by replacement with fibrous tissue was considered to result in the development of LV dysfunction and progression to HF. All processes are mediated by both death receptor and mitochondrial signalling and inadequate oxygen supply especially into cardiomyocyte subjected increased load in post-infarction heart may promote progressive cardiomyocyte loss and subsequent impairment of LV contractile function. Another possible mechanism of beneficial ITPP effects could involve salvage of peri-infarct borderzone, a thin layer of viable, but ischaemic myocardium.

ITPP was previously used in a heart failure model of transgenic mice overexpressing Gαq. As suggested in the piglets model, in this study a single dose of 1 and 2 g/kg markedly improved maximal exercise capacity; however, no attempts of chronic ITPP administration were undertaken, nor its effects on cardiac function or remodelling were tested. However, we and others have extensively studied ITPP in oncology setting in various animal models, alone or combined with chemotherapies, and have demonstrated its potent anti-cancer effects. These effects at least partially were attributable to normalization of abnormal tumour vasculature through prevention of overexpression of HIF pathway that emerged as the crucial pathway for the tumour progression.

In our experiments, in cultured cardiomyocytic murine cells we show that indeed ITPP is able to prevent overexpression of HIF-1. This could be one of crucial mechanisms of its effectiveness in heart failure model in vivo, since studies confirm that HIF-1α expression is indeed increased in myocardial samples from human failing hearts. In animal studies, overexpression of either HIF-1α or HIF-2α has been associated with the spontaneous development of cardiomyopathy: although HIF-1 overexpression protected the mouse heart against consequences of MI, reduced infarct size, improved cardiac function and increased capillary density after 4 weeks of follow-up, chronic HIF-1α overexpression resulted in spontaneous hypertrophy and impairment of ventricular function over 8 months in mice and in the model of aortic constriction was associated with impaired ventricular function. Furthermore, chronic HIF-1α overexpression led to development of spontaneous heart failure and premature death in transgenic mouse models. These studies suggest that while HIF-1 overexpression can be beneficial in the short term, its long-term effects, including metabolic reprogramming, defective angiogenesis and impairment of cardiomyocyte calcium handling, can be detrimental.

To test this hypothesis, we undertook detailed investigation of contraction and relaxation of isolated cardiomyocytes from those post-MI rats that were treated with ITPP or placebo for 4 weeks. As we have previously demonstrated, cardiomyocytes from post-MI hearts exhibited increased cell shortening, delayed time to peak contraction and relaxation. However, ITPP did not affect any of these parameters, suggesting that it had no effect on either contractility or relaxation. These results suggest that probably main mechanism of ITPP action in post-MI hearts does not involve normalization of Ca2+ handling. However, in our model these abnormalities of Ca2+ handling were modest at best, so maybe in other settings, when such changes could be more pronounced, presumable effects of ITPP could be revealed.

Another very interesting aspect of our study is the mechanism in which red blood cells previously charged with ITPP, react with
hypoxic cardiomyocytes resulting in oxygen release. Inherently to the red blood cells physiology, oxygen release gets more efficient when erythrocytes are delivered under flow conditions involving shear stress that more closely mimic the physiological situation.

On the other hand, ITPP itself, without red blood cells, was completely ineffective in our model, supporting the observation that it facilitates oxygen delivery by red blood cell haemoglobin rather than causing some intrinsic effects. Last but not least, ITPP did not exhibit any toxic effects, either in cultured murine cardiomyocytes, or in isolated rat cardiomyocytes or in situ rat hearts as evidence by morphological or functional investigations.

Therefore, we can conclude that ITPP is a promising agent for the treatment and prevention of heart failure through increased tissue oxygen delivery and reduction of HIF-1 expression may be one of its crucial potential mechanisms of action.

ACKNOWLEDGEMENTS
Authors wish to thank Professor Jean-Marie Lehn, USIAS, University of Strasbourg, 67083 Strasbourg, France for his support and collaboration in providing ITTP, and Professor Claude Nicolau, Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA 02115, USA, for his constant scientific interest. Thanks to David Gosset, for technical help in flow cytometry, Fabienne Fasani for cell handling. This work was supported by the Kosciuszko Grant N 579/2016/DA from the Polish Ministry of Defense, by Normoxys Inc under contract, within the research agreement between the Company and the University of Strasbourg.

CONFLICTS OF INTEREST
CN and CK are shareholders of Normoxys Inc.

AUTHOR CONTRIBUTIONS
M. Oknińska, A. Paterek, U. Mackiewicz and M. Maćzewski, conducted the in vivo experiments; B. El Hafny-Rahbi, C. Crola da Silva, K. Brodadzewska and C. Kieda conducted the in vitro experiments, M. Maćzewski and C. Kieda designed and monitored the project and wrote the manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Claudine Kieda https://orcid.org/0000-0002-7573-029X

REFERENCES
1. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation. 2000;102: lv14-lv23.
2. Sabbah HN. Silent disease progression in clinically stable heart failure. Eur J Heart Fail. 2017;19:469-478.
3. Ventura-Clapier R, Garnier A, Vekslar V, Joubert F. Bioenergetics of the failing heart. Biochim Biophys Acta. 2011;1813:1360-1372.
4. Nascimben L, Ingwall Joanne S, Paulettto P, et al. Creatine kinase system in failing and nonfailing human myocardium. Circulation. 1996;94:1894-1901.
5. Ingwall Joanne S, Weiss RG. Is the failing heart energy starved? Circ Res. 2004;95:135-145.
6. Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. New Engl J Med. 2013;368:1210-1219.
7. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New Engl J Med. 2009;361:2436-2448.
8. Paterak A, Kępska M, Sochanowicz B, et al. Beneficial effects of intravenous iron therapy in a rat model of heart failure with preserved systemic iron status but depleted intracellular cardiac stores. Sci Rep. 2018;8:15758.
9. Fylaktakidou KC, Lehn J-M, Greferath R, Nicolau C. Inositol triphosphosphate: a new membrane permeant allosteric effector of haemoglobin. Bioorg Chem Lett. 2005;15:1605-1608.
10. Duarte CD, Greferath R, Nicolau C, Lehn J-M. myo-Inositol Trisphosphate: A Novel Allosteric Effector of Hemoglobin with High Permeation Selectivity across the Red Blood Cell Plasma Membrane. ChemBioChem. 2010;11:2543-2548.
11. Kieda C, El Hafny-Rahbi B, Collet G, et al. Stable tumor vessel normalization with pO2 increase and endothelial PTEN activation by inositol triphosphophate brings novel tumor treatment. J Mol Med. 2013;91:883-899.
12. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12:5447-5454.
13. Semenza GL. Hypoxia-inducible factor 1 and cardiovascular disease. Annu Rev Physiol. 2014;76:39-56.
14. Bishop T, Ratcliffe PJ. HIF hydroxylase pathways in cardiovascular physiology and medicine. Circul Res. 2015;117:65-79.
15. Thomas LW, Ashcroft M. Exploring the molecular interface between hypoxia-inducible factor signalling and mitochondria. Cell Mol Life Sci. 2019;76:1759-1777.
16. Kieda C, Greferath R, Crola da Silva C, Fylaktakidou KC, Lehn J-M, Nicolau C. Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes. Proc Natl Acad Sci USA. 2006;103:15576-15581.
17. Kieda C, Paprocka M, Krawczenko A, et al. New human microvascular endothelial cell lines with specific adhesion molecules phenotypes. Endothelium. 2002;9:247-261.
18. Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol. 1996;271:C1172-C1180.
19. Kieda C, Greferath R, Crola da Silva C, Fylaktakidou KC, Lehn JM, Nicolau C. Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes. Proc Natl Acad Sci USA. 2006;103:15576-15581.
20. Bensley JG, De Matteo R, Harding R, Black MJ. Three-dimensional direct measurement of cardiomyocyte volume, necularity, and ploidy in thick histological sections. Sci Rep. 2016;6:23756.
21. Pagliaro BR, Cannata F, Stefanini GG, Bolognese L. Myocardial ischemia and coronary disease in heart failure. Heart Fail Rev. 2019. https://doi.org/10.1007/s10741-019-09831-z
22. Griggs DMJ, Chen C, Tchokoev V. Subendocardial anaerobic metabolism in experimental aortic stenosis. Am J Physiol. 1973;224:607-612.
23. Gulati A, Ismail TF, Ali A, et al. Microvascular dysfunction in dilated cardiomyopathy: a quantitative stress perfusion cardiovascular magnetic resonance study. JACC Cardiovasc Imaging. 2019;12:1699-1708.
24. Takashio S, Yamamuro M, Izumiya Y, et al. Coronary microvascular dysfunction and diastolic load correlate with cardiac troponin T release measured by a highly sensitive assay in patients with nonischemic heart failure. *J Am Coll Cardiol*. 2013;62:632-640.

25. Andre L, Fauconnier J, Reboul C, et al. Subendocardial increase in reactive oxygen species production affects regional contractile function in ischemic heart failure. *Antioxid Redox Signal*. 2012;18:1009-1020.

26. Yeboah J, Bluemke DA, Hundley WG, Rodriguez CJ, Lima JAC, Herrington DM. Left ventricular dilation and incident congestive heart failure in asymptomatic adults without cardiovascular disease: multi-ethnic study of atherosclerosis (MESA). *J Card Fail*. 2014;20:905-911.

27. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. *Circulation*. 1990;81:1161-1172.

28. Adameova A, Goncalvesova E, Szobi A, Dhalla NS. Necroptotic cell death in failing heart: relevance and proposed mechanisms. *Heart Fail Rev*. 2016;21:213-221.

29. Del Re DP, Amgalan D, Linkermann A, Liu Q, Kitsis RN. Fundamental mechanisms of regulated cell death and implications for heart disease. *Physiol Rev*. 2019;99:1765-1817.

30. Jackson BM, Gorman JH, Moainie SL, et al. Extension of border-zone myocardium in postinfarction dilated cardiomyopathy. *J Am Coll Cardiol*. 2002;40:1160-1167.

31. Biolo A, Greferath R, Siwik DA, et al. Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, <em>myo</em>-inositol trispyrophosphate. *Proc Natl Acad Sci*. 2009;106:1926-1929.

32. Teisseire BP, Ropars C, Vallez MO, Herigault RA, Nicolau C. Physiological effects of high-P50 erythrocyte transfusion on piglets. *J Appl Physiol*. 1985;1985(58):1810-1817.

33. Collet G, Skrzypek K, Grillon C, et al. Hypoxia control to normalize pathologic angiogenesis: potential role for endothelial precursor cells and miRNAs regulation. *Vasc Pharmacol*. 2012;56:252-261.

34. Collet G, Lamerant-Fayel N, Tertil M, et al. Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth. *Mol Cancer Ther*. 2014;13:165-178.

35. Hölscher M, Schäfer K, Krull S, et al. Unfavourable consequences of chronic cardiac HIF-1α stabilization. *Cardiovasc Res*. 2012;94:77-86.

36. Kido M, Du L, Sullivan CC, et al. Hypoxia-Inducible Factor 1-Alpha Reduces Infarction and Attenuates Progression of Cardiac Dysfunction After Myocardial Infarction in the Mouse. *J Am Coll Cardiol*. 2005;46:2116-2124.

37. Bekeredjian R, Walton CB, MacCannell KA, et al. Conditional HIF-1alpha expression produces a reversible cardiomyopathy. *PLoS ONE*. 2010;5:e11693-e.

38. Moslehi J, Minamishima Yoji A, Shi J, et al. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. *Circulation*. 2010;122:1004-1016.

39. Mączewski M, Mackiewicz U. Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart. *Cardiovasc Res*. 2008;79:42-51.

How to cite this article: Oknińska M, El-Hafny-Rahbi B, Paterek A, et al. Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol trispyrophosphate (ITPP)-enhancement of oxygen delivery by red blood cells. *J Cell Mol Med*. 2020;24:2272-2283. [https://doi.org/10.1111/jcmm.14909](https://doi.org/10.1111/jcmm.14909)